Pfizer PFE
Pfizer is a multinational pharmaceutical company that develops, manufactures, and markets medicines and vaccines for a wide range of diseases, including oncology, immunology, and rare diseases. Pfizer has solid financial health (score 6.91) and an attractive forward valuation (forward P/E 9.90), but its growth is weak (2.60%) and the 'patent cliff' is a structural risk that weighs on its prospects, with an unsustainable dividend payout (226%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Pfizer is a multinational pharmaceutical company that develops, manufactures, and markets medicines and vaccines for a wide range of diseases, including oncology, immunology, and rare diseases. Pfizer has solid financial health (score 6.91) and an attractive forward valuation (forward P/E 9.90), but its growth is weak (2.60%) and the 'patent cliff' is a structural risk that weighs on its prospects, with an unsustainable dividend payout (226%).
Score by category
| Category | Score |
|---|---|
| Financial health | 6.9 |
| Quality / Moat | 6.1 |
| Valuation | 5.5 |
| Growth | 4.5 |
| Dividend | 4.7 |
| Momentum | 6.4 |
| Risk & Context | 8.5 |
OVERALL SCORE: 6.1/10
Context and risks
Regulatory risk in the US is moderate, with pressure on drug pricing. Additionally, Pfizer's 'patent cliff' is a known business model risk, with several key patents expiring and the consequent loss of exclusivity.
News considered in the analysis
- Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? — El titular reconoce el riesgo del 'patent cliff' de Pfizer, un desafío estructural ya conocido y parcialmente descontado, pero que sigue siendo un lastre material para el crecimiento futuro.
- Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing? — La narrativa de 'turnaround' sugiere expectativas de mejora, pero es una opinión de analista sin un catalizador concreto, por lo que el impacto es moderado y parcialmente descontado.
- Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside? — Similar al anterior, es una comparativa de análisis que apunta a un potencial de recuperación, pero sin un evento específico que lo materialice.
- Pfizer (PFE) Balances Global Pricing Opportunity with New Revenue Sharing — La noticia menciona una nueva oportunidad de ingresos por 'revenue sharing', un modelo de negocio emergente que podría ser un catalizador positivo, aunque aún no está claro su impacto real.
- Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. — El sentimiento positivo hacia la innovación en biotecnología podría beneficiar a Pfizer, pero es una opinión general de mercado, no un hecho específico de la compañía.
Verdict: Hold, with caution. The forward valuation is attractive, but growth and dividend are at risk due to patent expirations.
Main risk: The 'patent cliff' is the main risk: the expiration of patents for key drugs will erode revenue and pressure margins, questioning the sustainability of the dividend.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →